Patent · US Active

Opioid formulations

US11110084B2 · kind B2 · utility

2Cited by

47References

30Claims

0Family size

Assignee

CAMURUS AB · SE

Inventors

Fredrik Tiberg · Lund, SE
Ian Harwigsson · Lund, SE
Markus Johnsson · Lund, SE

Key dates

Filing date	Jan 6, 2021
Grant date	Sep 7, 2021
Priority date	—
Expiry date	Jan 6, 2041

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P29/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A depot precursor formulation comprising:a) a controlled-release matrix;b) at least oxygen containing organic solvent;c) at least 12% by weigh of at least one active agent selected from buprenorphine and salts thereof, calculated as buprenorphine free base.Corresponding depot compositions and methods of treatment in pain management, by opioid maintenance and related methods are provided.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.